Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 21 of 156 for:    "Primary Central Nervous System Lymphoma"

[CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03569995
Recruitment Status : Recruiting
First Posted : June 26, 2018
Last Update Posted : May 24, 2019
Sponsor:
Collaborator:
Celltrion
Information provided by (Responsible Party):
Won Seog Kim, Samsung Medical Center

Brief Summary:
This study was conducted to evaluate the 2-year progression free survival rate of elderly patients with primary CNS lymphoma followed by combination of rituximab and methotrexate followed by rituximab and cytarabine.

Condition or disease Intervention/treatment Phase
Primary CNS Lymphoma Drug: Rituximab Drug: Methotrexate Drug: Cytarabine Phase 2

Detailed Description:

As described, standard therapy for patients with primary CNS lymphoma is not based on a high level of evidence yet, and studies in elderly patients with this disease are very limited. Based on the Korea National Cancer Incidence Database, it is estimated that about 100 ~ 150 cases of primary central nervous system lymphoma are diagnosed per year in Korea, but there is no analysis through prospective studies. As described previously, MTX monotherapy in elderly patients is relatively safe and does not reduce clinical utility. Although the autologous therapy may consider autologous stem cell transplantation, it is difficult to apply in elderly patients. Brain radiation therapy is not a primary consideration because it may cause neurological sequelae, especially in elderly patients. High-dose cytarabine is a safely administered drug that has been used extensively in clinical studies involving the treatment of elderly patients.Rituximab has not been studied prospectively for medications, doses, and intervals that are expected to play a role in patients with primary CNS lymphoma, as described above, and may be caused by reducing the number of cytotoxic anticancer drugs in elderly patients And to reduce the treatment effect.

Therefore, the authors propose a two-phase study in which R-A induction therapy is performed after R-M induction therapy in elderly patients with primary CNS lymphoma.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 35 participants
Intervention Model: Single Group Assignment
Intervention Model Description:

[Induction phase]

① After induction therapy (R-M) 2 times, first evaluation

  • Complete, partial response or stable disease-> next step
  • Progressive disease-> eliminated

    ② After Induction therapy (R-M) was added 3 times (total 5 times), 2nd evaluation

  • Complete response -> consolidation therapy progress
  • Partial response or stable disease-> R-M 2 additional administrations
  • Progressive disease-> eliminated

    ③ After Induction therapy (R-M) was added twice (7 times in total), 3rd evaluation

  • Complete, partial response or stable disease-> consolidation therapy
  • Progressive disease-> eliminated
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Combination of Rituximab and Methotrexate Followed by Rituximab and Cytarabine in Elderly Patients With Primary CNS Lymphoma
Actual Study Start Date : June 15, 2018
Estimated Primary Completion Date : June 15, 2024
Estimated Study Completion Date : June 15, 2025


Arm Intervention/treatment
Experimental: Induction+Consolidation chemotherapy

[Induction phase]

① After induction therapy (Rituximab-Methotrexate) 2 times, first evaluation

  • Complete, partial response or stable disease-> next step
  • Progressive disease-> eliminated

    ② After Induction therapy (Rituximab-Methotrexate) was added 3 times (total 5 times), 2nd evaluation

  • Complete response -> consolidation therapy(Rituximab-Cytarabine) progress
  • Partial response or stable disease-> Rituximab-Methotrexate 2 additional administrations
  • Progressive disease-> eliminated

    ③ After Induction therapy (Rituximab-Methotrexate) was added twice (7 times in total), 3rd evaluation

  • Complete, partial response or stable disease-> consolidation therapy(Rituximab-Cytarabine)
  • Progressive disease-> eliminated
Drug: Rituximab
500 mg/m2 + 5%DW 500 mL IVF Begin with 50 mg/hr (increase by 50 mg/hr per 30 min until 400 mg/hr is reached)

Drug: Methotrexate
500 mg/m2 + 5%DW 200 mL IV over 15 minutes 3000 mg/m2 + 5%DW 500 mL IVF over 3 hrs Concurrent hydration and subsequent leucovorin rescue is mandatory

Drug: Cytarabine
3000 mg/m2 + 5%DW 200 mL IVF over 2 hrs steroid eye drop 0.1%, 2 drops q 6hrs, on days 1-9




Primary Outcome Measures :
  1. 2-year progression free survival rate [ Time Frame: the time between the date of treatment start and the date of death due to any cause or date of disease, assessed up to 24 months ]
    From the end of the last patient's trial, the disease progression will be tracked for up to 2 years, and primary analysis and reporting will be conducted.


Secondary Outcome Measures :
  1. progression free survival [ Time Frame: 2 years from the date of consent to the date of Progress disease f / u. ]
    Means the period from the date of consent to the date of disease progression, the time of death, or the last time the disease has not progressed or has confirmed its survival.

  2. overall survival [ Time Frame: Time between the start of treatment and the date of death.assessed up to 5 years] ]
    It measures the time from start of treatment to death.

  3. Frequency of Adverse events classified by each criterion by CTCAE v4.0 [ Time Frame: from the date of informed consent signature to 31 days after last drug administration. ]
    CTCAE v4 (Common Terminology Criteria for Adverse Events v4.0) In the present study, toxicities will be recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Event (CTCAE), version 4.0. Then, the collected Toxicity is classified by CTCAE term and calculated as%, and a lot of AE will be detected.

  4. time to treatment failure [ Time Frame: Within 3 years ]
    Means the period from the date of consent to the date of the onset of the disease or to the discontinuation of treatment for any reason.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   60 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically proven diagnosis of B-cell non-Hodgkin's lymphoma, exclusively localized in the central nervous system, cranial nerves, and/or eyes
  2. No previous treatment; A tumorectomy on diagnostic purpose and/or use of glucocorticoids is allowed
  3. Measurable lesion(s)
  4. Age ≥ 60 years
  5. Unfit patients for high-dose chemotherapy followed by autologous stem cell transplantation
  6. Adequate organ functions

    • Absolute Neutrophil Count (ANC) ≥ 1.0 x 109/L
    • Platelets ≥ 50 x 109/L
    • Hemoglobin ≥ 8.0 g/dL
    • Serum Creatinine ≤ 1.5 x upper limit normal (ULN)
    • Serum Bilirubin ≤ 1.5 x ULN
    • AST and ALT ≤ 3 x ULN
  7. Patients with adequately controlled HBV, HCV or HIV are allowed. In case of HBV (+), adequate anti-viral prophylaxis should be incorporated. In case of HIV (+), highly active anti-retroviral therapy should be incorporated.
  8. Written informed consent
  9. ECOG performance scale 0, 1 or 2
  10. Life expectancy > 3 months

Exclusion Criteria:

  1. T-cell or NK/T cell lymphoma
  2. Any evidence of systemic non-Hodgkin's lymphoma as demonstrated by computed tomography scan of the neck, chest, abdomen, and pelvis and bone marrow examinations
  3. Young and fit patients who are suitable for high-dose chemotherapy followed by autologous stem cell transplantation
  4. Prior radiation therapy on target CNS lesion(s)
  5. Concurrent severe or uncontrolled medical conditions, laboratory abnormalities or psychiatric disorders that would preclude the participants in the study by the discretion of attending physicians
  6. Metachronous malignancy other than adequately treated basal cell or squamous cell carcinoma of the skin, or CIN of uterine cervix, or prostate cancer that can be observed without treatment
  7. Known hypersensitivity to the investigational agent(s)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03569995


Contacts
Layout table for location contacts
Contact: Wonseog Kim, M.D 82-3410-6548 wonseog.kim@samsung.com
Contact: Seokjin Kim, M.D 82-3410-1766 seokjin88.kim@samsung.com

Locations
Layout table for location information
Korea, Republic of
Samsung Medical Center Recruiting
Seoul, Gangnam-gu,, Korea, Republic of, 06351
Contact: Kaeun Park, CRA    82-70-7014-4162    kaeun.park@samsung.com   
Sponsors and Collaborators
Won Seog Kim
Celltrion
Investigators
Layout table for investigator information
Principal Investigator: Wonseog Kim, M.D Samsung Medical Center

Layout table for additonal information
Responsible Party: Won Seog Kim, Clinical Professor, Samsung Medical Center
ClinicalTrials.gov Identifier: NCT03569995     History of Changes
Other Study ID Numbers: 2017-12-103
First Posted: June 26, 2018    Key Record Dates
Last Update Posted: May 24, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Rituximab
Methotrexate
Cytarabine
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents
Nucleic Acid Synthesis Inhibitors
Antiviral Agents
Anti-Infective Agents